EGFR and non-small cell lung carcinoma: Osimertinib, the third-generation EGFR TKI used as the current first-line treatment for NSCLC patients who are EGFR-positive, showed disease-free survival (DFS) improvement in the overall population compared to first-generation EGFR TKIs.